|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.81 - 34.98|
|52 Week Range||27.04 - 34.98|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||22.75|
|Forward Dividend & Yield||1.07 (3.08%)|
|1y Target Est||37.90|
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumoursApproval supported by the data.
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.
Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
Swiss pharmaceutical giant Roche Pharmaceuticals became the first security on OTC Markets to reach $4 billion in dollar trading volume in 2019, according to OTC Markets data. Dollar volume in the Swiss ...
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.
OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
SOUTH SAN FRANCISCO, Calif.-- -- There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis or microscopic polyangiitis The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis If approved, this ...
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB. Roche's new diagnostics boss, Thomas Schinecker, fills a post that had been led for months on an interim basis by Michael Heuer, who is retiring. Roche's diagnostics unit includes diabetes care, sophisticated laboratory equipment and tests aimed at personalizing cancer treatment.